| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000009510 |
| Receipt No. | R000011175 |
| Scientific Title | A Phase II/III Randomized multicenter Trial of Intersphincteric resection (ISR) with or without Preoperative Chemotherapy for very low-lying Rectal Cancer |
| Date of disclosure of the study information | 2012/12/20 |
| Last modified on | 2019/12/28 (Ver. 9) |
| Basic information | ||
| Public title | A Phase II/III Randomized multicenter Trial of Intersphincteric resection (ISR) with or without Preoperative Chemotherapy for very low-lying Rectal Cancer | |
| Acronym | Neo-adjuvant chemotherapy for Intersphincteric resection (ISR) in Low Rectal Cancers
NAIR. Study |
|
| Scientific Title | A Phase II/III Randomized multicenter Trial of Intersphincteric resection (ISR) with or without Preoperative Chemotherapy for very low-lying Rectal Cancer | |
| Scientific Title:Acronym | Neo-adjuvant chemotherapy for Intersphincteric resection (ISR) in Low Rectal Cancers
NAIR. Study |
|
| Region |
|
|
| Condition | |||
| Condition | Very Low Rectal Cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | Improvement of disease free survival including local recurrence rate |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | Phase II,III |
| Assessment | |
| Primary outcomes | PhaseII : Evaluation of safety in all treatment course ( operation, chemotherapy)
PhaseIII : Disease free survival at three years |
| Key secondary outcomes | Overall survival at three years,
Rate of curative operation. Postoperative anal function and QOL, Tumor response to neoadjuvant chemotherapy, adverse events in chemotherapy, |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | YES |
| Dynamic allocation | YES |
| Institution consideration | Institution is considered as adjustment factor in dynamic allocation. |
| Blocking | NO |
| Concealment | Pseudo-randomization |
| Intervention | |||
| No. of arms | 2 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | A : ISR plus adjuvant chemotherapy | ||
| Interventions/Control_2 | B : ISR with neoadjuvant chemotherapy plus adjuvant chemotherapy | ||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Primary rectal cancer located within 5cm from the anal verge, or located within 3cm from the dentate line.
2) Pathological proven adenocarcinoma. 3) Clinical T3 N any M0 4) No invasion to the external sphincter by preoperative imaging diagnosis 5) Possible to be curative resection 6) Aged 20 to 75 years old 7) Enough organ functions i. WBC count > 3,000/mm3 ii. Platelet count > 100,000/ mm3 iii. Hemoglobin > 8.0 g/dl iv. AST < 100 IU/L v. ALT < 100IU/L vi. T.Bil < 2.0mg/dl vii. Cr < 1.5mg/dl viii. PT Consumption > 50% 8) PS of 0 or 1 9) Without previous radiotherapy and chemotherapy 10) Written informed consent |
|||
| Key exclusion criteria | 1) Patients with request of abdominoperineal resection (APR)
2) Patients with impossibility for ISR 3) Patients with poor anal function preoperatively 4) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in site or mucosal carcinoma 5) Patients with serious diseases as follows i. Uncontrollable diabetes mellitus ii. Uncontrollable hypertension iii. Interstitial pneumonia, pulmonary fibrosis, or severe emphysema 6) Chronic active hepatitis type B. Positive for HCV 7) Episodes of blood transfusion within the post 14 days 8) Patients with severe mental disease 9) Cannot agree on this study 10) Unsuitable patients for this study |
|||
| Target sample size | 200 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | National Cancer Center Hospital East | ||||||
| Division name | Colorectal and Pelvic Surgery | ||||||
| Zip code | 277-8577 | ||||||
| Address | 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan | ||||||
| TEL | 04-7133-1111 | ||||||
| maito@east.ncc.go.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | National Cancer Center Hospital East | ||||||
| Division name | Colorectal and Pelvic Surgery | ||||||
| Zip code | 277-8577 | ||||||
| Address | 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan | ||||||
| TEL | 04-7133-1111 | ||||||
| Homepage URL | |||||||
| yutsukad@east.ncc.go.jp | |||||||
| Sponsor | |
| Institute | National Cancer Center Hospital East |
| Institute | |
| Department | |
| Funding Source | |
| Organization | National Cancer Center |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Institutional review board of National Cancer Center |
| Address | 5-1-1, Tyuoku Tsukiji, Tokyo |
| Tel | 03-3542-2511 |
| irst@ml.res.ncc.go.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 国立がん研究センター東病院(千葉県)
国立がん研究センター中央病院(東京都) 久留米大学(福岡県) 藤田保健衛生大学(愛知県) 防衛医科大学校(埼玉県) 帝京ちば総合医療センター(千葉県) 愛知県がんセンター中央病院(愛知県) 青森県立中央病院(青森県) 静岡県立静岡がんセンター(静岡県) 大阪府立成人病センター(大阪府) 高野病院(熊本県) 埼玉県立がんセンター(埼玉県) 東京女子医科大学(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011175 |